E.I. STUKOVA, Yu.V. KENIKSFEST, N.P. TOROPOVA

 Ural Scientific Research Institute of Dermatovenerology and Immunopathology, 8 Shcherbakov Str., Ekaterinburg, Russian Federation, 620076

 Stukova E.I. — dermatovenerologist of the Department of Chronic Dermatosis in Adults, Junior Researcher of the Scientific and Clinical Department of Dermatology, e-mail: [email protected], ORCID ID: 0000-0003-4580-7839

Keniksfest Yu.V. — D. Sc. (medicine), Associate Professor, Leading Researcher of the Scientific and Clinical Department of Dermatology, Head of the Department of Chronic Dermatosis in Adults, e-mail: [email protected], ORCID ID: 0000-0001-8431-5664

Toropova N.P. — Ph. D. (medicine), Leading Researcher of the Research and Education Department, e-mail: [email protected], ORCID ID: 0000-0002-7849-1124

 To evaluate the clinical efficacy of a combined topic therapy in patients with atopic dermatitis complicated by secondary pyogenic infection without systemic antibacterial drugs.

Material and methods. 60 patients with atopic dermatitis complicated by secondary pyogenic infection were under observation. Two treatment options were used: complex treatment in accordance with standards and clinical recommendations and complex treatment including a combined topic agent containing betamethasone and mupirocin.

Results. Clinical features of atopic dermatitis complicated by a secondary infection are presented. Brief information on the role of S. aureus in the development of pyogenic processes on the skin in patients with atopic dermatitis is given. The analysis of the microbiota species composition from the affected skin sites in patients with severe atopic dermatitis complicated by a secondary infection is presented. A new index is proposed for the clinical evaluation of the severity of secondary infection in dermatological patients.

The conclusions. The clinical efficacy of the combined topic agent was demonstrated, without including systemic antibacterial drugs in the complex therapy.

Key words: atopic dermatitis, Staphylococcus aureus, skin microflora, antibiotic resistance, betamethasone dipropionate, mupirocin, combined topic therapy, index for evaluating the severity of pyogenic manifestations in patients with dermatoses.

(For citation: Stukova E.I., Keniksfest Yu.V., Toropova N.P. Modern features of the clinical course of atopic dermatitis complicated by a secondary infection. Choice of therapy tactics. Practical Medicine. 2018.)

REFERENCES

1. Leung, D.Y. New insights into atopic dermatitis: role of skin barrier and immune dysregulation. Allergol. Int, 2013, vol. 62, pp. 151–161.
2. Kubanova A.A., Kubanov A.A., Karamova A.E. et al. Perspective directions in the treatment of atopic dermatitis. Vestnik dermatologii i venerologii, 2017, no. 5, pp. 34–46.
3. Stukova E.I., Kenikfest Yu.V. Pathogenetic significance of Staphylococcus aureus in atopic dermatitis (literature review). Fundamentalʹnye issledovaniya, 2013, no. 7 (3), pp. 680–687 (in Russ.).
4. Stukova E.I., Kenikfest Yu.V., Kokhan M.M. et al. Modern clinical and pathogenetic aspects of secondary pyogenic complications in patients with allergic dermatoses, current approaches to therapy. Lechashchiy vrach, 2015, no. 5, pp. 39–44 (in Russ.).
5. Fluer F.S., Kudryavtseva A.V., Prokhorov V.Ya. Effect of Staphylococcus aureus Enterotoxins and Epidermidis on the Course of Atopic Dermatitis in Children. Pediatriya, 2009, no. 2 (87), pp. 43–48 (in Russ.).
6. Chung H.J., Jeon H.S., Sung H. et al. Epidemiological characteristics of methicillin-resistant Staphylococcus aureus isolates from children with eczematous atopic dermatitis lesions. J. Clin. Microbiol, 2008, vol. 46 (3), pp. 991–995.
7. Gong J.Q., Lin L., Lin T. et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br. J. Dermatol, 2006, vol. 155 (4), pp. 680–687.
8. Federalʹnye klinicheskie rekomendatsii. Dermatovenerologiya 2015; Bolezni kozhi. Infektsii peredavaemye polovym putem, pod red. Kubanovoy A.A. 5-e izd., pererab. i dop. [Federal clinical guidelines. Dermatovenereology 2015; Skin diseases. Sexually transmitted infections, ed. by A.A. Kubanova. 5th ed., Revised and enlarged]. Moscow: Delovoy ehkspress, 2016. 768 p.
9. Samtsov A.V., Statsenko A.V., Khayrutdinov V.R., Chaplygin A.V. Comparative study of the clinical efficacy of 3% tetracycline ointment and 2% mupirocin ointment in the treatment of pyoderma. Vestnik dermatologii i venerologii, 2012, no. 3, pp. 86–90 (in Russ.).
10. Liu X., Deng S., Huang J. et al. Dissemination of macrolides, fusidic acid and mupirocin resistance among Staphylococcus aureus clinical isolates. Oncotarget, 2017, vol. 8 (35), pp. 58086–58097.
11. Gheda S.F., Khalil M.A. In vitro and in vivo preliminary results on Spirulina platensis for treatment of impetigo: Topical cream application. Afr. J. Biotechnol, 2012, vol. 12 (18), pp. 2498–2509.
12. Lovino S.M., Krantz K.D., Blanco D.M. et al. NVC-422 topical gel for the treatment of impetigo. Int. J. Clin. Exp. Pathol, 2011, vol. 4 (6), pp. 587–595.